Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol

Soner,Burak  Cem; Aktug,Huseyin; Acikgoz,Eda; Duzagac,Fahriye; Guven,Ummu; Ayla,Sule; Cal,Cag; Oktem,Gulperi

doi:10.3892/ijmm.2014.1930

Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol

Authors:
- Burak Cem Soner
- Huseyin Aktug
- Eda Acikgoz
- Fahriye Duzagac
- Ummu Guven
- Sule Ayla
- Cag Cal
- Gulperi Oktem
View Affiliations

Affiliations: Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Pharmacology, 42100, Konya, Turkey, Ege University Faculty of Medicine, Department of Histology and Embryology, Bornova 35100, Izmir, Turkey, Ege University Health Science Institute, Department of Stem Cell, 35100, Izmir, Turkey, Zeynep Kamil Gynecology and Maternity Training and Research Hospital, Department of Obstetrics and Gynecology, 34668 Istanbul, Turkey, Izmir University of Economics, Faculty of Health Sciences, 35330, Izmir, Turkey
Published online on: September 11, 2014 https://doi.org/10.3892/ijmm.2014.1930
Pages: 1249-1256
Copyright: © Soner et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Flavopiridol is a flavone that inhibits several cyclin‑dependent kinases and exhibits potent growth‑inhibitory activity, apoptosis and G1‑phase arrest in a number of human tumor cell lines. Flavopiridol is currently undergoing investigation in human clinical trials. The present study focused on the effect of flavopiridol in cell proliferation, cell cycle progression and apoptosis in prostate cancer stem cells (CSCs). Therefore, cluster of differentiation 133 (CD133)+high/CD44+high prostate CSCs were isolated from the DU145 human prostate cancer cell line. The cells were treated with flavopiridol in a dose‑ and time‑dependent manner to determine the inhibitory effect. Cell viability and proliferation were analyzed and the efficiency of flavopiridol was assessed using the sphere‑forming assay. Flavopiridol was applied to monolayer cultures of CD133high/CD44high human prostate CSCs at the following final concentrations: 100, 300, 500 and 1000 nM . The cultures were incubated for 24, 48 and 72 h. The half maximal inhibitory concentration (IC50) value of the drug was determined as 500 nM for monolayer cells. Dead cells were analyzed prior and subsequent to exposure to increasing flavopiridol doses. Annexin‑V and immunofluorescence analyses were performed for the evaluation of apoptotic pathways. According to the results, flavopiridol treatment caused significant growth inhibition at 500 and 1000 nM when compared to the control at 24 h. G0/G1 analysis showed a statistically significant difference between 100 and 500 nM (P<0.005), 100 and 1000 nM (P<0.001), 300 and 1000 nM (P<0.001), and 500 and 1000 nM (P<0.001). Flavopiridol also significantly influenced the cells in the G2/M phase, particularly at high‑dose treatments. Flavopiridol induced growth inhibition and apoptosis at the IC50 dose (500 nM), resulting in a significant increase in immunofluorescence staining of caspase‑3, caspase‑8 and p53. In conclusion, the present results indicated that flavopiridol could be a useful therapeutic agent for prostate CSCs by inhibiting tumor growth and malignant progression, and inducing apoptosis.

View Figures

View References

1	Naik RG, Kattige SL, Bhat SV, Alreja B, de Souza NJ and Rupp RH: An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron. 44:2081–2086. 1988. View Article : Google Scholar
2	Newcomb EW, Tamasdan C, Entzminger Y, et al: Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle. 2:243–250. 2003. View Article : Google Scholar
3	Grant S and Dent P: Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what’s in a name? Mol Cancer Ther. 3:873–875. 2004.
4	König A, Schwartz GK, Mohammad RM, Al-Katib A and Gabrilove JL: The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood. 90:4307–4312. 1997.
5	Hooijberg JH, Broxterman HJ, Scheffer GL, et al: Potent interaction of flavopiridol with MRP1. Br J Cancer. 81:269–276. 1999. View Article : Google Scholar : PubMed/NCBI
6	Cimica V, Smith ME, Zhang Z, Mathur D, Mani S and Kalpana GV: Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC Cancer. 10:6342010. View Article : Google Scholar : PubMed/NCBI
7	Chen R, Keating MJ, Gandhi V and Plunkett W: Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 106:2513–2519. 2005. View Article : Google Scholar : PubMed/NCBI
8	Senderowicz AM: Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs. 17:313–320. 1999. View Article : Google Scholar : PubMed/NCBI
9	Stadler WM, Vogelzang NJ, Amato R, et al: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol. 18:371–375. 2000.PubMed/NCBI
10	Budak-Alpdogan T, Chen B, Warrier A, Medina DJ, Moore D and Bertino JR: Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma. Clin Cancer Res. 15:1232–1240. 2009. View Article : Google Scholar : PubMed/NCBI
11	Meacham CE and Morrison SJ: Tumour heterogeneity and cancer cell plasticity. Nature. 501:328–337. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kreso A and Dick JE: Evolution of the cancer stem cell model. Cell Stem Cell. 14:275–291. 2014. View Article : Google Scholar : PubMed/NCBI
13	La Porta CA: Mechanism of drug sensitivity and resistance in melanoma. Curr Cancer Drug Targets. 9:391–397. 2009.PubMed/NCBI
14	Goksel G, Bilir A, Uslu R, Akbulut H, Guven U and Oktem G: WNT1 gene expression alters in heterogeneous population of prostate cancer cells; decreased expression pattern observed in CD133⁺/CD44⁺ prostate cancer stem cell spheroids. J BUON. 19:207–214. 2014.PubMed/NCBI
15	Oktem G, Bilir A, Uslu R, Inan SV, Demiray SB, Atmaca H, Ayla S, Sercan O and Uysal A: Expression profiling of stem cell signaling alters with spheroid formation in CD133^high/CD44^high prostate cancer stem cells. Oncol Lett. 7:2103–2109. 2014.PubMed/NCBI
16	Ayla S, Bilir A, Soner BC, Yilmaz-Dilsiz O, Erguven M and Oktem G: Notch signaling-related therapeutic strategies with novel drugs in neuroblastoma spheroids. J Pediatr Hematol Oncol. 36:37–44. 2014. View Article : Google Scholar : PubMed/NCBI
17	Wirger A, Perabo FG, Burgemeister S, et al: Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res. 25:4341–4347. 2005.PubMed/NCBI
18	Chien M, Astumian M, Liebowitz D, Rinker-Schaeffer C and Stadler WM: In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol. 44:81–87. 1999. View Article : Google Scholar : PubMed/NCBI
19	Nelson DM, Joseph B, Hillion J, Segal J, Karp JE and Resar LM: Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma. 52:1999–2006. 2011. View Article : Google Scholar
20	Smith ME, Cimica V, Chinni S, Challagulla K, Mani S and Kalpana GV: Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res. 14:523–532. 2008. View Article : Google Scholar : PubMed/NCBI
21	Mayer F, Mueller S, Malenke E, Kuczyk M, Hartmann JT and Bokemeyer C: Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Invest New Drugs. 23:205–211. 2005. View Article : Google Scholar : PubMed/NCBI
22	Taniai M, Grambihler A, Higuchi H, et al: Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 64:3517–3524. 2004. View Article : Google Scholar : PubMed/NCBI
23	Decker RH, Dai Y and Grant S: The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ. 8:715–724. 2001. View Article : Google Scholar
24	Villela L and Bolaños-Meade J: Acute myeloid leukaemia: optimal management and recent developments. Drugs. 71:1537–1550. 2011. View Article : Google Scholar : PubMed/NCBI
25	Lamb R, Lehn S, Rogerson L, Clarke RB and Landberg G: Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle. 12:2384–2394. 2013. View Article : Google Scholar : PubMed/NCBI
26	Yao Y, Shi J, Zhang Z, Zhang F, Ma R and Zhao Y: The radiation-sensitizing effect of flavopiridol in the esophageal cancer cell line Eca109. Oncol Lett. 5:1872–1876. 2013.PubMed/NCBI
27	Chao SH, Fujinaga K, Marion JE, et al: Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem. 275:28345–28348. 2000. View Article : Google Scholar : PubMed/NCBI
28	Carlson B, Lahusen T, Singh S, et al: Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 59:4634–4641. 1999.PubMed/NCBI
29	Chao SH and Price DH: Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem. 276:31793–31799. 2001. View Article : Google Scholar : PubMed/NCBI
30	de Azevedo WF Jr, Canduri F and da Silveira NJ: Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun. 293:566–571. 2002.PubMed/NCBI